Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA vaccine (HBV large S protein) refers to therapeutic messenger RNA (mRNA) vaccines designed to express the large surface (S) protein of the hepatitis B virus (HBV) to treat chronic hepatitis B (CHB). A notable preclinical candidate under this category is a codon-optimized mRNA vaccine encoding the full-length HBV large S protein delivered via chitosan nanoemulsions (mRNA@CNE), developed by researchers at Zhejiang University. This vaccine is designed to overcome HBV-induced immune tolerance and stimulate robust cytotoxic memory T-cell responses. In animal models, sequential quadruple therapy combining this mRNA vaccine with entecavir, an antisense oligonucleotide, and interferon-alpha successfully induced a durable functional cure in 50% of carrier mice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mRNA vaccine (HBV large S protein).